Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension

NCT00797316 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00797316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00797316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2008
Completion date
December 31, 2009
Enrollment
532 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension